VRCA
Verrica Pharmaceuticals Inc. Common StockstockNASDAQ
verrica pharmaceuticals inc., a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the united states. the company's lead product candidate include vp-102 that is in phase iii clinical trial for the treatment of molluscum contagiosum; in phase ii clinical trial for the treatment of common warts; and completed phase i clinical trial for the treatment of genital warts. it is also developing cantharidin-based product candidate, vp-103 for the treatment of plantar warts. the company has a license agreement with lytix biopharma as to develop and commercialize ltx-315 for dermatologic oncology indications. verrica pharmaceuticals inc. was founded in 2013 and is headquartered in west chester, pennsylvania.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 3.91 | 2026-11-11 | -25.83% | 3.237 |
| 1M | 3.44 | 2026-10-19 | -15.70% | 3.226 |
| 3M | 4.68 | 2026-08-18 | -38.03% | 2.385 |
| 6M | 5.87 | 2026-05-18 | -50.60% | 1.551 |
| 1Y | 3.83 | 2025-11-18 | -24.28% | 2.280 |
| 2Y | 8.88 | 2024-11-18 | -67.35% | — |
| 5Y | 112.60 | 2021-11-18 | -97.42% | 1.043 |
Verrica Pharmaceuticals Inc. Common Stock (NASDAQ:VRCA) stock price today is $2.90, and today's volume is 44,476. VRCA is down 7.643% today. The 30 day average volume is 60,431. VRCA market cap is $49.82M with 17.18M shares outstanding.